Literature DB >> 1346769

Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease.

N J Bell1, R H Hunt.   

Abstract

Gastro-oesophageal reflux disease is a common condition with a complex pathophysiology. Despite the spectrum of abnormalities, gastric acid has a central role in mucosal damage, and the mainstay of medical treatment is suppression of gastric acid secretion. The results of antisecretory treatment as assessed by endoscopic healing are reviewed. H2 receptor antagonists give more rapid symptom relief than placebo and can produce endoscopic improvement in 31-88% of cases depending on the severity of oesophagitis. Complete healing, however, is seen only in 27-45% of patients and these have mainly grades I-II disease. Improved healing rates can be obtained by increasing the degree of acid suppression or the length of treatment. The addition of a prokinetic agent may be beneficial. Omeprazole heals 67-92% of patients overall and although most successful in the lower grades of oesophagitis, can also heal 48-62% of patients with grade IV disease. The degree and rate of healing seem to be related to the reduction in oesophageal acid exposure and thus may correlate with the degree and duration of acid suppression over 24 hours obtained by the various treatments. The underlying pathophysiology is unchanged, however, and long term treatment may be needed to maintain remission.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1346769      PMCID: PMC1373877          DOI: 10.1136/gut.33.1.118

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  68 in total

1.  Time-course of development and reversal of gastric endocrine cell hyperplasia after inhibition of acid secretion. Studies with omeprazole and ranitidine in intact and antrectomized rats.

Authors:  H Larsson; E Carlsson; R Håkanson; H Mattsson; G Nilsson; R Seensalu; B Wallmark; F Sundler
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

2.  Medical therapy for chronic reflux esophagitis. Long-term follow-up.

Authors:  D A Lieberman
Journal:  Arch Intern Med       Date:  1987-10

3.  Healing and relapse of severe peptic esophagitis after treatment with omeprazole.

Authors:  D J Hetzel; J Dent; W D Reed; F M Narielvala; M Mackinnon; J H McCarthy; B Mitchell; B R Beveridge; B H Laurence; G G Gibson
Journal:  Gastroenterology       Date:  1988-10       Impact factor: 22.682

4.  Cisapride versus ranitidine in the treatment of reflux esophagitis.

Authors:  H D Janisch; W Hüttemann; M H Bouzo
Journal:  Hepatogastroenterology       Date:  1988-06

5.  Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial.

Authors:  O Grove; C Bekker; M G Jeppe-Hansen; E Karstoft; G Sanchez; C K Axelsson; H O Nielsen; B Andersen; J Rask-Madsen
Journal:  Scand J Gastroenterol       Date:  1985-05       Impact factor: 2.423

6.  Treatment of severe reflux esophagitis with cimetidine and metoclopramide.

Authors:  D A Lieberman; E B Keeffe
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

7.  Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis.

Authors:  R F Harvey; P C Gordon; N Hadley; D E Long; T R Gill; R I Macpherson; B C Beats; A J Tottle
Journal:  Lancet       Date:  1987-11-21       Impact factor: 79.321

8.  Ranitidine and placebo in the treatment of reflux oesophagitis. A double-blind randomized trial.

Authors:  J A Goy; J H Maynard; W M McNaughton; A O'Shea
Journal:  Med J Aust       Date:  1983-11-26       Impact factor: 7.738

9.  Ranitidine vs metoclopramide in the medical treatment of reflux esophagitis.

Authors:  M Guslandi; P A Testoni; S Passaretti; E Masci; E Ballarin; U Comin; R Marchi; G Ronchi; A Tittobello
Journal:  Hepatogastroenterology       Date:  1983-06

10.  Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.

Authors:  W C Orr; M G Robinson; T J Humphries; J Antonello; A Cagliola
Journal:  Aliment Pharmacol Ther       Date:  1988-06       Impact factor: 8.171

View more
  40 in total

1.  What is heartburn worth? A cost-utility analysis of management strategies.

Authors:  G R Heudebert; R M Centor; J C Klapow; R Marks; L Johnson; C M Wilcox
Journal:  J Gen Intern Med       Date:  2000-03       Impact factor: 5.128

2.  Effects of structured follow-up and of more effective acid inhibitory treatment in the management of GORD patients in a Swedish primary-care setting: a randomized, open-label study.

Authors:  Rickard Ekesbo; Svante Sjöstedt; Heléne Sörngård
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

3.  Diagnostic interpretation of extended pH monitoring: is there a single best method?

Authors:  Vasundhara Tolia; Anne Wuerth; Ronald Thomas
Journal:  Dig Dis Sci       Date:  2005-01       Impact factor: 3.199

4.  Predictable prolonged suppression of gastric acidity with a novel proton pump inhibitor, AGN 201904-Z.

Authors:  R H Hunt; D Armstrong; M Yaghoobi; C James; Y Chen; J Leonard; J M Shin; E Lee; D Tang-Liu; G Sachs
Journal:  Aliment Pharmacol Ther       Date:  2008-04-25       Impact factor: 8.171

5.  The Inhibitory Effect of Quercetin-3-O-beta-D-Glucuronopyranoside on Gastritis and Reflux Esophagitis in Rats.

Authors:  Young Sil Min; Se Eun Lee; Seung Tae Hong; Hyun Sik Kim; Byung-Chul Choi; Sang Soo Sim; Wan Kyun Whang; Uy Dong Sohn
Journal:  Korean J Physiol Pharmacol       Date:  2009-08-31       Impact factor: 2.016

6.  Head-to-head comparison of H2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: a meta-analysis.

Authors:  Wei-Hong Wang; Jia-Qing Huang; Ge-Fan Zheng; Harry Hua-Xiang Xia; Wai-Man Wong; Shiu-Kum Lam; Benjamin Chun-Yu Wong
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

7.  Antileishmanial activity of the antiulcer agent omeprazole.

Authors:  Suping Jiang; Juliana Meadows; Steven A Anderson; Antony J Mukkada
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety.

Authors:  J Dent; N D Yeomans; M Mackinnon; W Reed; F M Narielvala; D J Hetzel; E Solcia; D J Shearman
Journal:  Gut       Date:  1994-05       Impact factor: 23.059

9.  Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease.

Authors:  J M Marrero; J S de Caestecker; J D Maxwell
Journal:  Gut       Date:  1994-04       Impact factor: 23.059

Review 10.  Insights into the future of gastric acid suppression.

Authors:  Kenneth R DeVault; Nicholas J Talley
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-09       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.